​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $361.00, with a high of $385.00 and a low of $338.00. This represents a 11.15% increase from the last price of $324.79.

$100 $160 $220 $280 $340 $400 High: $385 Avg: $361 Low: $338 Last Closed Price: $324.79

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 38 Buy (77.55%), 9 Hold (18.37%), 2 Sell (4.08%), and 0 Strong Sell (0.00%).

Buy
Total 49 2 9 38 0 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals11.15%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts1210
Avg Price Target$385.00$372.50$337.20
Last Closing Price$324.79$324.79$324.79
Upside/Downside18.54%14.69%3.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25111371133
Jun, 25121271133
May, 25121281134
Apr, 25121281-33
Mar, 25111191-32
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 21, 2025Danielle BrillTruist Financial$385.00$324.4918.65%18.54%
Jun 24, 2025Kostas BiliourisBMO Capital$360.00$325.0010.77%10.84%
Mar 21, 2025Scotiabank$338.00$283.3419.29%4.07%
Jan 07, 2025William PickeringBernstein$310.00$235.9531.38%-4.55%
Oct 24, 2024Whitney IjemCanaccord Genuity$336.00$294.8713.95%3.45%
Oct 01, 2024Whitney IjemCanaccord Genuity$366.00$273.6933.73%12.69%
Sep 27, 2024Tazeen AhmadBank of America Securities$307.00$274.9111.67%-5.48%
Aug 27, 2024Kostas BiliourisBMO Capital$300.00$269.3111.40%-7.63%
Aug 26, 2024Luca IssiRBC Capital$300.00$271.4310.53%-7.63%
Aug 16, 2024Salveen RichterGoldman Sachs$370.00$262.7040.85%13.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2025BMO CapitalOutperformOutperformhold
Mar 21, 2025ScotiabankOutperformOutperformhold
Jan 07, 2025BernsteinOutperformOutperformhold
Oct 24, 2024Canaccord GenuityBuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 01, 2024Canaccord GenuityBuyBuyhold
Sep 27, 2024Bank of America SecuritiesBuyBuyhold
Sep 03, 2024OppenheimerPerformPerformhold
Sep 03, 2024Wolfe ResearchNegativeNegativehold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.46$-7.20$-9.30$-3.52-----
Avg Forecast$-7.20$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-6.05$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-8.50$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %3.61%11.80%3.91%1.15%-----

Revenue Forecast

$0 $2B $3B $5B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$492.85M$844.29M$1.04B$1.83B$2.25B----
Avg Forecast$475.26M$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$541.27M$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$416.86M$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %3.70%2.86%2.38%0.12%0.35%----

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-858.28M$-852.82M$-1.13B$-440.24M$-278.16M----
Avg Forecast$-777.85M$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-622.28M$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-933.41M$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %10.34%17.93%46.82%--16.28%----

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 38 Buy, 9 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 49 Wall Street analysts, averages $361 over the next 12 months. The price target range spans from $338 at the low end to $385 at the high end, suggesting a potential 11.15% change from the previous closing price of $324.79.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a 11.15% upside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • July 2025: 33.33% Strong Buy, 39.39% Buy, 21.21% Hold, 3.03% Sell, 3.03% Strong Sell.
  • June 2025: 36.36% Strong Buy, 36.36% Buy, 21.21% Hold, 3.03% Sell, 3.03% Strong Sell.
  • May 2025: 35.29% Strong Buy, 35.29% Buy, 23.53% Hold, 2.94% Sell, 2.94% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.04, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $2.91 in 2026, $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $2.65B, reflecting a 17.76% increase from the reported $2.25B in 2024. The forecast for 2026 is $3.54B, followed by $4.54B for 2027, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-197M, representing a -29.22% decrease from the reported $-278M in 2024. Projections indicate $330.06M in 2026, $942.06M in 2027, and $1.53B in 2028.